Exai Bio announced non-small cell lung cancer data further validating that its novel RNA- and generative AI-based liquid biopsy platform detected early-stage disease with high accuracy.
Io Therapeutics, Inc., announced the publication in Scientific Reports – Nature Publishing Group, of results from studies done with the company’s novel anti-cancer compound IRX4647, an agonist of the retinoic acid nuclear receptor gamma, discovered in the company’s oncology drug program.
CymaBay Therapeutics, Inc. announced the pricing of its previously announced underwritten public offering of common stock and pre-funded warrants.
Bioretec Ltd, a pioneering company dedicated to advancing biodegradable orthopedic implants, has signed a distribution agreement for the U.S. market with Spartan Medical Inc.
MaaT Pharma and Skyepharma announced that a significant development milestone has been reached with the completion of the facility and the transfer of MaaT Pharma’s Production and Development teams to the new site.
Foresee Pharmaceuticals, announced that the company presented the positive primary outcomes of its aderamastat Phase 2 proof-of-concept allergic asthma study at the European Respiratory Society International Congress 2023 taking place in Milan, Italy from September 9-13, 2023.
Evofem Biosciences, Inc. announced it has successfully negotiated and entered into a fourth amendment to its Securities Purchase and Security Agreement dated April 2020, as amended, with a U.S.-based, healthcare-focused institutional investor, under which the Investor purchased $25 million of convertible senior secured promissory notes from Evofem.
Evofem Biosciences Successfully Amends S.P.A. with Institutional Investor Read More »
Humacyte, Inc., a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale, announced the presentation of results from a Food and Drug Administration -regulated, investigator-sponsored clinical study conducted at the Mayo Clinic.
Clover Biopharmaceuticals, Ltd. (Clover; HKEX: 02197) today announced the launch of AdimFlu-S (QIS) in mainland China, where it is the only imported quadrivalent seasonal influenza vaccine approved for use in individuals aged three years and older.
Clover Launches Quadrivalent Seasonal Influenza Vaccine in Mainland China Read More »
HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that it has completed patient enrollment of a bridging study of tazemetostat in China.
